Coughlin, J.M., Yang, T., Rebman, A.W., et al. (2018) Imaging Glial Activation in Patients with Post-Treatment Lyme Disease Symptoms: A Pilot Study Using [11C]DPA-713 PET. Journal of Neuroinflammation, 15, 346.
https://doi.org/10.1186/s12974-018-1381-4

has been cited by the following article:

• TITLE: Antabuse for Lyme Disease: The Way Forward

  AUTHORS: David S. Younger, Beverley F. Murphy

  KEYWORDS: Disulfiram, Antabuse, Lyme Disease, Immune Globulin Therapy

  JOURNAL NAME: World Journal of Neuroscience, Vol.10 No.1, November 29, 2019

  ABSTRACT: Despite leadership by dedicated lay organization and patient-based advocacy groups, the way forward for prospective candidates for disulfiram treatment has been difficult. This article provides the background, overview of disulfiram, in particular its intended use in post-treatment Lyme disease syndrome after a standard of care course of antibiotics fails to alleviate symptoms of tick borne disease. A series of recommendations are offered to guide patients and clinicians.